Navigation Links
Researchers develop first transgenic monkey model of Huntington's disease
Date:5/18/2008

Scientists have developed the first genetically altered monkey model that replicates some symptoms observed in patients with Huntington's disease, according to a new study funded by the National Institutes of Health. Researchers are now able to better understand this complex, devastating and incurable genetic disorder affecting the brain. This advance, reported in the May 18 advance of online publication edition of Nature, could lead to major breakthroughs in the effort to develop new treatments for a range of neurological diseases.

Huntingtons is an inherited disease caused by a defective gene that triggers certain nerve cells in the brain to die. Symptoms may include uncontrolled movements, mood swings, cognitive decline, balance problems, and eventually losing the ability to walk, talk or swallow. It affects five to 10 people in every 100,000. There is no known treatment to halt progression of the disease, only medications to relieve symptoms. Death typically occurs 15 to 20 years after onset.

This study marks the first time that researchers have developed a rhesus macaque model of a specific human disease using transgenic technologies, a marked improvement over mouse models. Transgenic animals are created using a recombinant DNA method to modify a genome.

This research allows scientists to advance beyond mouse models which do not replicate all of the changes in the brain and behavior that humans with Huntingtons disease experience, said John D. Harding, Ph.D., director of primate resources at the NIHs National Center for Research Resources (NCRR), which funded the study. Primate models better mirror human diseases and are a critical link between research with small laboratory animals and studies involving humans.

To unravel the genetic components of this disease, NIH-supported researchers Anthony W.S. Chan, D.V.M., Ph.D.; Xiao-Jiang Li, M.D., Ph.D.; and Shi-Hua Li, M.D., Ph.D., collaborated with their colleagues at the Yerkes National Primate Research Center and other components of Emory University in Atlanta. The research was supported by the NCRR and the National Institute of Neurological Disorders and Stroke (NINDS) at NIH.

The Emory research team developed this transgenic monkey model by introducing altered forms of the Huntington gene into monkey eggs using a viral vector. The eggs were fertilized and the resulting embryos were introduced into surrogate mothers, resulting in five live births. The investigators are now studying the onset of the disease and its behavioral and cognitive effects, with the goal of using the monkey model to better understand disease mechanisms and to design therapies.

Genetic advances make it easy to identify who has inherited the disease gene, said Walter Koroshetz, M.D., deputy director of the NINDS. Now, with a primate model of Huntingtons disease, we are one large step closer to finding better treatments for people with the disease as well as those destined to develop it.

The Yerkes primate center where this advance was made is one of eight supported by NCRR. The centers provide leadership, training and resources to foster scientific discovery and compassionate, quality animal care. Last year, the eight centers located around the country supported more than 2,000 researchers studying a wide range of diseases using non human primate models.

Yerkes primate center is an ideal place to carry out this work because of its expertise in nonhuman primate transgenesis, non-invasive neural imaging, and experience with behavior assessment, said Dr. Harding.


'/>"/>

Contact: Joyce McDonald
info@ncrr.nih.gov
301-435-0888
NIH/National Center for Research Resources
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... asset protection and financial planning services to families and business owners in the ... aimed at supporting children with developmental disabilities. , The Lakemary Center is a ...
(Date:1/18/2017)... ... January 18, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that Mr. Michael Merges, ... upcoming WCBP Conference, to be held at the Mayflower Hotel, Washington DC, on ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... the revolutionary Active Brake Technology (ABT), an innovative braking system that allows skaters ... Brake Technology addresses one of the biggest concerns of beginner and intermediate skaters ...
(Date:1/17/2017)... Michigan (PRWEB) , ... January 17, 2017 , ... January is National Stalking Awareness ... who choose to lurk in the corners and commit the crime of stalking, a very ... use and addiction, an often overlooked factor in stalking and other crimes. , “Stalking: know ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... point of difference. Eden Activewear is a stand-out company for several differences from ... online and only manufacture on demand, this is called 'Agile' manufacturing - ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
(Date:1/18/2017)... Safe Rx LLC and Good Day Pharmacy, ... Loveland, Colorado , today announced the availability ... Day locations.     "Patients with prescriptions prone ... storage," said Milton Cohen , President & CEO ... a cup of coffee, you can protect your children ...
(Date:1/18/2017)... In China , we say Health is ... China,s Healthy Strategy originates. 2016 is ... and Social Development of the People,s Republic of ... council of the People,s Republic of China ... plan, identifying medical devices as one of the main breakthrough ...
Breaking Medicine Technology: